Divalproex Sodium Tablet, Delayed Release
Product Images NDC 68180-265

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68180-265). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 01)

FDA Label Image

Figure 2 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 02)

FDA Label Image

Fig 2 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 03)

This appears to be a graph or chart displaying the percentage reduction in CPS (unknown acronym) rate for patients taking Divalproex Sodium Delayed-Release Tablets compared to a placebo. The graph shows that 50% of patients experienced improvement, while the other half either saw no change or worsening. Not enough information is available to provide more context.*

FDA Label Image

Fig 3 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 04)

This text appears to be a chart or graph showing the reduction in CPS (cycles per second) rate for patients receiving high and low doses of a treatment. It shows that 50% of patients experienced improvement in their CPS rate, while some experienced no change and others experienced worsening. The exact treatment, condition, or context for this data is not available.*

FDA Label Image

Figure 4 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 05)

This text indicates the presence of two studies related to delayed-release tablets of Divalproex Sodium, with one of them including a placebo. No further information is provided.*

FDA Label Image

Fig 6 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 06)

This is a description of Divalproex Sodium tablets manufactured by Lupin Pharmaceuticals Inc. The tablets are delayed-release type and are available in bottles containing 100 tablets, with each tablet containing 125mg of the active ingredient. The tablets are not to be accepted if the bottle seal is broken. The NDC number for this product is 68180-265-01. The text also includes dosage information and the manufacturer's address.*

FDA Label Image

Fig 7 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 07)

This is a prescription medication called Divalproex Sodium Delayed-Release Tablets USP. Each tablet contains 250mg of the active ingredient, divalproex sodium equivalent to valproic acid. The tablets should be kept in a cool and dry place between 20-25°C. This medication is manufactured by Lupin Limited and comes in a container with 100 tablets. The NDC (National Drug Code) for this specific package is 68180-266-01. Usual dosage information is not available.*

FDA Label Image

Figure 8 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 08)

This is medication information for Divalproex Sodium Delayed-Release Tablets sold by Lupin Pharmaceuticals. It shows the NDC (National Drug Code), the drug's active ingredient (divalproex sodium USP), and the strength (500 mg of valproic acid). The text also provides information about the drug's usual dosage, storage instructions, and manufacturer. The text is accompanied by a lot number and expiration date.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.